Ultragenyx Pharmaceutical | RARE - Operating Profit


Ultragenyx Pharmaceutical reported $-114M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Acadia Pharmaceuticals USD 35.76M 3.38M Sep/2025
Agios Pharmaceuticals USD -121.58M 4.71M Dec/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
BioCryst Pharmaceuticals USD -2.54M 10.23M Dec/2024
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Esperion Therapeutics USD -16.03M 18.6M Sep/2024
Immunic USD -25.73M 2.91M Sep/2024
Insmed USD -249.71M 11.64M Dec/2025
Ionis Pharmaceuticals USD -215M 54.82M Dec/2025
Karyopharm Therapeutics USD -31.28M 5M Dec/2024
Kyowa Hakko Kirin JPY 38.35B 12.49B Dec/2025
MacroGenics USD 18.64M 55.4M Sep/2025
Moderna USD -857M 597M Dec/2025
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
PTC Therapeutics USD -81.62M 85.11M Dec/2025
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025
Xoma USD -15.64M 5.56M Sep/2024